• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

Blood 2011 Dec 22;118(26):6793-802

MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of interleukin-12 signaling in human natural killer cells.

Huang Y, Lei Y, Zhang H, Hou L, Zhang M, Dayton AI

Abstract

Interleukin (IL)-12 exerts a number of regulatory effects on natural killer (NK) cells by activating IL-12 signaling. IL-12 signaling is tightly auto-regulated to control its onset and termination, with prolonged IL-12 treatment resulting in IL-12 hyporesponsiveness. However, the mechanisms underlying IL-12 auto-regulation are still unclear. In this study we report that prolonged IL-12 treatment significantly upregulates microRNAs (miRNAs), including miR-132, -212, and -200a in primary human NK cells. This up-regulation correlates temporally with gradually decreasing STAT4 levels and decreasing IFN-gamma expression, after an initial increase within the first 16 hours of IL-12 treatment. The IL-12 hyporesponsiveness is dependent on IL-12 concentration, and associated up-regulation of miR-132, -212, and -200a. Furthermore, IL-12-hyporesponsive cells regain responsiveness of IFN-gamma production 24 hours after IL-12 removal, which correlates with decreases in miR-132, -212, and -200a levels. Over-expression of miR-132, -212, and -200a by transfection into NK cells mimics IL-12 priming, inducing IL-12 hyporesponsiveness, whereas transfection of miR-132, -212, and -200a inhibitors largely abolishes IL-12 induction of IL-12 hyporesponsiveness. These data suggest that miR-132, -212, and -200a up-regulation during prolonged IL-12 treatment, negatively regulates the IL-12 signaling pathway by reducing STAT4 expression in primary human NK cells.


Category: Journal Article
PubMed ID: #22077060 DOI: 10.1182/blood-2011-05-356162
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2011-11-15 Entry Last Modified: 2012-08-29
Feedback
-
-